Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 7/20 | 0.59 |
| ▸ | AGTR1 | P30556 | 4/20 | 0.59 |
| ▸ | NTSR2 | O95665 | 3/20 | 0.49 |
| ▸ | NTSR1 | P30989 | 3/20 | 0.49 |
| ▸ | F2 | P00734 | 4/20 | 0.49 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.48 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.48 |
| ▸ | CALCR | P30988 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Talfirastide SCHEMBL15926158 | 0.95 | AGTR1 (0.59) | AGTR2AGTR1NTSR2NTSR1F2 | |
| SCHEMBL29701258 | 0.91 | AGTR2 (0.55) | AGTR2AGTR1NTSR2NTSR1F2 | |
| SCHEMBL29602954 | 0.89 | C5AR1 (0.55) | AGTR2AGTR1NTSR2NTSR1SORT1 | |
| SCHEMBL29972916 | 0.89 | AGTR1 (0.62) | AGTR2AGTR1NTSR2NTSR1F2 | |
| SCHEMBL9510693 | 0.89 | AGTR1 (0.60) | AGTR2AGTR1NTSR2NTSR1F2 | |
| Angiotensin-Ii SCHEMBL29973063 | 0.89 | AGTR2 (0.62) | AGTR2AGTR1NTSR2NTSR1F2 | |
| SCHEMBL7052378 | 0.89 | AGTR2 (0.65) | AGTR2AGTR1NTSR2NTSR1F2 | |
| SCHEMBL30901127 | 0.89 | C5AR1 (0.52) | AGTR2AGTR1NTSR2NTSR1F2 | |
| SCHEMBL10924118 | 0.88 | AGTR1 (0.53) | AGTR2AGTR1NTSR2NTSR1F2 | |
| Angiotensin Ii SCHEMBL9013957 | 0.88 | AGTR2 (0.69) | AGTR2AGTR1NTSR2NTSR1F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140220055-A1 | WT1 PEPTIDE CANCER VACCINE COMPOSITION FOR TRANSDERMAL ADMINISTRATION | INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC. (JP) | 2014-08-07 | — | — | US | disclosed |
| US-20140220105-A1 | TAPE PREPARATION OF WT1 PEPTIDE CANCER VACCINE FOR TRANSDERMAL ADMINISTRATION | INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC. (JP) | 2014-08-07 | — | — | US | disclosed |
| US-20140220059-A1 | WT1 PEPTIDE CANCER VACCINE COMPOSITION FOR MUCOSAL ADMINISTRATION | INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC. (JP) | 2014-08-07 | — | — | US | disclosed |
| US-20140220079-A1 | VACCINE COMPOSITION FOR MUCOSAL ADMINISTRATION | NITTO DENKO CORPORATION (JP) | 2014-08-07 | — | — | US | disclosed |
| US-20140220057-A1 | WT1 PEPTIDE CANCER VACCINE COMPOSITION FOR TRANSDERMAL ADMINISTRATION | INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC. (JP) | 2014-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140220105-A1 | TAPE PREPARATION OF WT1 PEPTIDE CANCER VACCINE FOR TRANSDERMAL ADMINISTRATION | TAP1, TAP2, MICA | AGTR2 2299/4885AGTR1 1637/4885NTSR2 2542/4885 |
| US-20140220057-A1 | WT1 PEPTIDE CANCER VACCINE COMPOSITION FOR TRANSDERMAL ADMINISTRATION | TAP1, TAP2, MUC1 | AGTR2 633/4885AGTR1 466/4885NTSR2 864/4885 |
| US-20140220055-A1 | WT1 PEPTIDE CANCER VACCINE COMPOSITION FOR TRANSDERMAL ADMINISTRATION | TAP1, TAP2, MICA | AGTR2 1622/4885AGTR1 1355/4885NTSR2 1380/4885 |
| US-20140220079-A1 | VACCINE COMPOSITION FOR MUCOSAL ADMINISTRATION | MUC1, ERBB2, TLR5 | AGTR2 2837/4885AGTR1 3510/4885NTSR2 442/4885 |
| US-20140220059-A1 | WT1 PEPTIDE CANCER VACCINE COMPOSITION FOR MUCOSAL ADMINISTRATION | MUC1, TAP1, MICA | AGTR2 2376/4885AGTR1 1941/4885NTSR2 2437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.